1.Tenover, FC, McGowan, JE Jr. Epidemiology and molecular biology of antimicrobial resistance in bacteria. In: Nelson, AM, Horsburgh, CR Jr, eds. Pathology of Emerging Infections—2. Washington, DC: American Society for Microbiology Press; 1998:343–360.
2.Sanders, WE Jr, Sanders, CC. Circumventing antibiotic resistance in specialized hospital units. Clin Microbiol Infect 1997;3:272–273.
3.McGowan, JE Jr, Tenover, FC. Control of antimicrobial resistance in the health care system. Infect Dis Clin North Am 1997;11:297–311.
4.Goosens, H, Sprenger, MJW. Community acquired infections and bacterial resistance. BMJ 1998;317:654–657.
5.Gniadkowski, M, Palucha, A, Grzesiowski, P, Hryniewicz, W. Outbreak of ceftazidime-resistant Klebsiella pneumoniae in a pediatric hospital in Warsaw, Poland: clonal spread of the TEM-47 extended-spectrum beta-lactamase (ESBL)-producing strain and transfer of a plasmid carrying the SHV-5-like ESBL-encoding gene. Antimkrob Agents Chemother 1998;42:3079–3085.
6.O'Brien, FG, Pearman, JW, Gracey, M, Riley, TV, Grubb, WB. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 1999;37:2858–2862.
7.Trick, WE, Kuehnert, MJ, Quirk, SB, Arduino, MJ, Aguero, SM, Carson, LA, et al. Regional dissemination of vancomycin-resistant enterococci resulting from interfacility transfer of colonized patients. J Infect Dis 1999;180:391–396.
8.McGowan, JE Jr. Drug resistance and nosocomial infections: epidemiology and prevention strategies. In: Finch, RG, Williams, RJ, eds. Balliere's Clinical Infectious Diseases. London, UK: Balliere Tindall; 1999;5:177–192.
9.Amyes, SGB. Genes and spectrum: the theoretical limits. Clin Infert Dis 1998;27(suppl 1):S21–S28.
10.Hawkey, PM. The origins and molecular basis of antibiotic resistance. BMJ 1998;317:657–660.
11.Kim, W-J, Weinstein, RA, Hayden, MKThe changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. J Infect Dis 1999;179:163–171.
12.Tenover, FC, McGowan, JE Jr. Reasons for the emergence of antibiotic resistance. Am J Med Sci 1996;311:9–16.
13.Baquero, F, Negri, M-C, Morosini, M-I, Blazquez, J. Antibiotic-selective environments. Clin Infect Dis 1998;27(suppl 1):S5–S11.
14.McGowan, JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994;15:478–483.
15.Johnson, AP. Antibiotic resistance among clinically important gram-positive bacteria in the UK J Hosp Infect 1998;40:17–26.
16.Monnet, DL, Archibald, LK, Phillips, L, Tenover, FC, McGowan, JE Jr, Gaynes, RP. Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modeling. Intensive Care Antimicrobial Resistance Epidemiology Project and National Nosocomial Infection Surveillance System Hospitals. Infect Control Hosp Epidemiol 1998;19:388–394.
17.Fridkin, SK, Steward, CD, Edwards, JR, Pryor, ERMcGowan, JE Jr, Archibald, LK, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999;29:245–252.
18.Archibald, L, Phillips, L, Monnet, D, McGowan, JE Jr, Tenover, F, Gaynes, RAntimicrobial resistance in isolates from inpatients and outpatients in the United States: the increasing importance of the intensive care unit. Clin Inject Dis 1997;24:211–215.
19.Gaynes, RMonnet, D. The contribution of antibiotic use on the frequency of antibiotic resistance in hospitals. In: Antibiotic Resistance: Origins, Evolution, Selection, and Spread. Ciba Foundation Symposium 207. Chichester, England: John Wiley and Sons; 1997:47–60.
20.Fridkin, SK, Edwards, JRPichette, SC, Pryor, ER, McGowan, JE Jr, Tenover, FC, et al. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis 1999;28:1119–1125.
21.Wenzel, RP, Wong, MT. Editorial response: managing antibiotic use— impact of infection control. Clin Infert Dis 1999;28:1126–1127.
22.Polk, ROptimal use of modern antibiotics: emerging trends. Clin Infect Dis 1999;29:264–274.
23.McGowan, JE Jr. Ways and means to influence antimicrobial prescribing in healthcare and its impact on resistance. In: Andremont, A, Brun-Buisson, C, McGowan, JE Jr, eds. Maurice Rapin Colloquia: Antibiotic Therapy and Control of Antimicrobial Resistance in Hospitals. Paris, France: Elsevier; 1999:97–105.
24.McGowan, JE Jr, Gerding, DN. Does antibiotic restriction prevent resistance? New Horizons 1996;4:370–376.
25.Munoz, RCoffey, TJ, Daniels, M, Dowson, CG, Laible, G, Casal, J, et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 1991;164:302–306.
26.Belongia, EA, Schwartz, B. Strategies for promoting judicious use of antibiotics by doctors and patients. BMJ 1998;317:668–671.
27.Burke, JP. Antibiotic resistance—squeezing the balloon? JAMA 1998;280:1270–1271.
28.Stosor, V, Peterson, LRPostelnick, M, Noskin, GA. Enterococcus faecium bacteremia—does vancomycin resistance make a difference? Arch Intern Med 1998;158:522–527.
29.Turnidge, J. What can be done about resistance to antibiotics? BMJ 1998;317:645–647.
30.Phillips, I. Lessons from the past: a personal view. Clin Infect Dis 1998;27(suppl 1):S2–S4.
31.Marwick, C. Animal feed antibiotic use raises drug resistance iear. JAMA 1999;282:120–122.
32.Helmuth, RProtz, D. How to modify conditions limiting resistance in bacteria in animal and other reservoirs. Clin Infect Dis 1997;24(suppl 1):S136–S138.
33.Duncan, RA. Controlling use of antimicrobial agents. Infect Control Hosp Epidemiol 1997;18:260–266.
34.Lipsky, BA, Baker, CA, McDonald, LL, Suzuki, NT. Improving the appropriateness of vancomycin use by sequential interventions. Am J Infect Control 1999;27:84–90.
35.Metlay, JP, Stafford, RS, Singer, DE. National trends in the use of antibiotics by primary care physicians for adult patients with cough. Arch Intern Med 1998;158:1813–1818.
36.Levy, SB. Multidrug resistance—a sign of the times. N Engl J Med 1998;338:1376–1378.
37.Kollef, MH, Sherman, G, Ward, S, Fraser, VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–474.
38.McGowan, JE Jr. Antibiotic-resistant bacteria and healthcare systems— four steps for effective response. Infect Control Hosp Epidemiol 1995;18:67–70.
39.Schentag, JJ. Antibiotic dosing—does one size fit all? JAMA 1998;279:159–160.
40.Classen, DC. Clinical decision support systems to improve clinical practice and quality of care. JAMA 1998;280:1360–1361.
41.Kolmos, HJ, Little, P. Should general practitioners perform diagnostic tests on patients before prescribing antibiotics? BMJ 1999;318:799–802.
42.Martin, C, Pourriat, JL. Quality of perioperative antibiotic administration by French anaesthetists. J Hosp Infect 1998;40:47–53.
43.Pichichero, ME. Changing the treatment paradigm for acute otitis media in children. JAMA 1998;279:1748–1750.
44.Culpepper, L, Froom, J. Routine antimicrobial treatment of acute otitis media: is it necessary? JAMA 1997;278:1643–1645.
45.Hamilton-Miller, JMT. Switch therapy: the theory and practice of early change from parenteral to non-parenteral antibiotic administration. Clin Microbiol Infection 1996;2:12–19.
46.Parker, SE, Nathwani, D, O'Reilly, D, Parkinson, S, Davey, PG. Evaluation of the impact of non-inpatient IV antibiotic treatment for acute infections on the hospital, primary care services and the patient. J Antimkrob Chemother 1998;42:373–380.
47.Dunagan, WC, Medoff, G. Formulary control of antimicrobial usage. What price freedom? Diagn Mkrobiol Infect Dis 1993;16:265–274.
48.Landman, D, Chockalingam, M, Quale, JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999;28:1062–1068.
49.Schentag, JJ, Hyatt, JM, Carr, JR, Paladino, JA, Birmingham, MC, Zimmer, GS, et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis 1998;26:1204–1214.
50.Evans, ME, Mulheim, ET, Rapp, RP. Vancomycin use in a university medical center: effect of a vancomycin continuation form. Infect Control Hosp Epidemiol 1999;20:417–420.
51.Pena, C, Pujol, M, Ardanuy, C, Ricart, A, Pallares, R, Linares, J, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimkrob Agents Chemother 1998;42:53–58.
52.Quale, J, Landman, D, Saurina, G, Atwood, E, Ditore, V, Patel, K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020–1050.
53.Rahal, JJ, Urban, C, Horn, D, Freeman, K, Segal-Maurer, S, Maurer, J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in Klebsiella. JAMA 1998;280:1233–1237.
54.White, AC Jr, Atmar, RL, Wilson, J, Cate, TR, Stager, CE, Greenberg, SB. Effects of requiring prior authorization for selected antimicrobials; expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230–239.
55.Mitchell, P. Antibiotic swings and roundabouts. Lancet 1998;352:1288.
56.Postelnick, MJ, Peterson, LR, Noskin, GAEffect of changes in antimicrobial agent use on bacterial pathogens recovered from hospitalized patients: a 6-year assessment. J Clinical Outcomes Management 1998;5:21–32.
57.Schwartz, B, Bell, DM, Hughes, JM. Preventing the emergence of antimicrobial resistance. A call for action by clinicians, public health officials, and patients. JAMA 1997;278:944–945.
58.van der Zwet, WC, Parlevliet, GASavelkoul, PH, Stoof, J, Kaiser, AM, Koeleman, JG, et al. Nosocomial outbreak of gentamicin-resistant Klebsiella pneumoniae in a neonatal intensive care unit controlled by a change in antibiotic policy. J Hosp Infect 1999;42:295–302.
59.Moellering, RC Jr. Antibiotic resistance: lessons for the future. Clin Infect Dis 1998;27(suppl 1):S135–S140.
60.Heizmann, WR. Circumventing antibiotic resistance in specialized hospital units. Clin Microbiol Infect 1997;3:133–134.
61.Rice, LB. Editorial response: a silver bullet for colonization and infection with methicillin-resistant Staphylococcus aureus still eludes us. Clin Infect Dis 1999;28:1067–1070.
62.Friedrich, LV, White, RL, Bosso, JAImpact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes. Clin Infect Dis 1999;28:1017–1024.
63.Streulens, MJ, Byl, B, Vincent, J-LAntibiotic policy: a tool for controlling resistance of hospital pathogens. Clin Microbiol Infect 1999;5(suppl):S19–S24.
64.Gerding, DN, Larson, TAHughes, RAWeiler, M, Shanholtzer, C, Peterson, LR. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimkrob Agents Chemother 1991;35:1284–1290.
65.Bonten, MJM, Slaughter, S, Ambergen, AW, et al. The role of “colonization pressure” in the spread of vancomycin-resistant enterococci. An important infection control variable. Arch Intern Med 1998;158:1127–1132.
66.Boyce, JM. It is time for action: improving hand hygiene in hospitals. Ann Intern Med 1999;130:153–155.